Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Biocon failed to provide critical information about proposed denosumab product, Amgen claims | Company expects ‘sales erosion’ of Prolia and XGEVA in 2025 driven by biosimilar competition | Sandoz launched interchangeable versions of bone drugs last month following settlement in 2024.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Samsung Biologics faces suit from Amgen over bone biosimilars

15 August 2024 Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products.

Biotechnology

Amgen and Sandoz settle dispute over blockbuster bone condition drugs

30 April 2024 Agreement clears the way for Sandoz to launch denosumab biosimilars in May 2025 | Dispute over multiple patents covering Prolia and Xgeva resolved.

Americas

Amgen sues generic drug maker over bone treatments

4 May 2023 Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.

More features

Too busy to save time? Why IP teams can’t afford to wait on AI

AZ counsel warns: EU Bolar exemption is ‘painful’ for pharma innovators

Novartis moves to quash SCOTUS review of Entresto case

Pfizer beats Novo Nordisk in $10bn bidding war

‘I need them and they need me’: Regeneron counsel on what makes a strong law firm partnership

7 in-house counsel tips for partnering with AI vendors

Patent applications for bio-cosmetics double in five years

Sun Pharma and BMS lead 2025 ANDA litigation

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

More on this story

Editor's picks

Editor's picks

More features